Patents by Inventor Junya Toguchida

Junya Toguchida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220246231
    Abstract: A plurality of metabolites contained in culture supernatants of a plurality of iPS cell clones whose differentiation efficiency into chondrocytes or neural crest cells is known is quantified, and a relationship between the measured values of the plurality of metabolites obtained by the quantification and the differentiation efficiencies is subjected to a multivariate analysis, and a model for predicting a differentiation efficiency of iPS cells is constructed. Furthermore, the plurality of metabolites contained in a culture supernatant of a test cell group including a single type of iPS cell clones is quantified, and the values, obtained by the quantification, are applied to the model, thereby predicting a differentiation efficiency of the test cell group into chondrocytes or neural crest cells. This makes it possible to predict the differentiation efficiency of iPS cells into chondrocytes or neural crest cells in a short time.
    Type: Application
    Filed: July 9, 2019
    Publication date: August 4, 2022
    Applicants: SHIMADZU CORPORATION, KYOTO UNIVERSITY
    Inventors: Makoto WATANABE, Taka-Aki SATO, Junya TOGUCHIDA
  • Patent number: 11207303
    Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: December 28, 2021
    Assignees: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
  • Publication number: 20210087531
    Abstract: The present invention provides a method for inducing osteogenic differentiation, the method comprising the following steps of: (1) culturing pluripotent stem cells under feeder-free conditions, (2) culturing the cells in a mixed culture medium of an osteogenic induction medium and a pluripotent stem cell medium, the mixed culture medium containing a ROCK inhibitor and a retinoic acid receptor ? or ? agonist, and (3) culturing the cells in an osteogenic induction medium containing the retinoic acid receptor ? or ? agonist. The method for inducing osteogenic differentiation according to the present invention is a simple, short-term, highly efficient and highly reproducible one-procedure method for inducing osteogenic differentiation, wherein the method is suitable for bone regeneration therapies, the development of bone metabolic drugs and the development of novel therapies for bone diseases.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Junya Toguchida, Shunsuke Kawai, Hiroyuki Yoshitomi, Cantas Alev
  • Patent number: 10947508
    Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 16, 2021
    Assignees: AJINOMOTO CO., INC., Kyoto University
    Inventors: Yonghui Jin, Ikue Harata, Sho Senda, Hiroki Ozawa, Tsuyoshi Kobayashi, Junya Toguchida, Makoto Ikeya
  • Publication number: 20200140946
    Abstract: Provided is a method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells. Provided is a genetic marker for predicting differentiation potential of undifferentiated iPS cells into cartilage cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells based on gene expression data of the undifferentiated iPS cells. A method of predicting differentiation potential of undifferentiated iPS cells into cartilage cells by predicting differentiation potential of the iPS cells into neural crest cells (NC cells) based on gene expression data of the undifferentiated iPS cells.
    Type: Application
    Filed: June 8, 2018
    Publication date: May 7, 2020
    Applicants: Shimadzu Corporation, Kyoto University
    Inventors: Makoto Watanabe, Taka-Aki Sato, Junya Toguchida
  • Patent number: 10260068
    Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 16, 2019
    Assignees: Sumitomo Dainippon Pharma Co., Ltd., Kyoto University
    Inventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
  • Publication number: 20180353485
    Abstract: The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: December 13, 2018
    Applicants: Kyoto University, Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Junya Toguchida, Makoto Ikeya, Akira Ohta, Kyosuke Hino
  • Patent number: 9921212
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Kyoto University
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
  • Publication number: 20170211070
    Abstract: The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 27, 2017
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., Kyoto University
    Inventors: Kyosuke Hino, Junya Toguchida, Makoto Ikeya
  • Publication number: 20170198258
    Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.
    Type: Application
    Filed: February 17, 2017
    Publication date: July 13, 2017
    Applicants: AJINOMOTO CO., INC., Kyoto University
    Inventors: Yonghui JIN, lkue HARATA, Sho SENDA, Hiroki OZAWA, Tsuyoshi KOBAYASHI, Junya TOGUCHIDA, Makoto IKEYA
  • Publication number: 20160177406
    Abstract: A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.
    Type: Application
    Filed: October 9, 2015
    Publication date: June 23, 2016
    Applicant: KYOTO UNIVERSITY
    Inventors: Junya Toguchida, Ryuta Nishikomori, Koji Yokoyama, Makoto Ikeya, Toshio Heike
  • Publication number: 20120316241
    Abstract: The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.
    Type: Application
    Filed: July 2, 2012
    Publication date: December 13, 2012
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Junya TOGUCHIDA
  • Publication number: 20110143425
    Abstract: Disclosed is a tissue-derived biomaterial carrier device (1) comprising a carrier case 810), an arm (125) provided upright on an interior bottom wall surface of the carrier case (10), a mounting part (121), a swing mechanism (122), a temperature control box (20) provided detachably on an exterior wall surface of the carrier case (10), and a heater (201) provided in the temperature control box (20). The mounting part (121) receives the mounting of a housing vessel in which a tissue-derived biomaterial is housed (an opening part (121a)). The swing mechanism (122) swingably supports the mounting part (121) relative to the arm (125). With the temperature control box (20) mounted on the carrier case (10), the heater (201) in the temperature control box (20) receives the supply of electric power from a battery (203) and regulates the temperature within the carrier case (10).
    Type: Application
    Filed: July 23, 2009
    Publication date: June 16, 2011
    Inventors: Junya Toguchida, Tomoki Aoyama, Kazuo Umihira
  • Publication number: 20100190685
    Abstract: The present invention relates to uses of sarcopodin as a gene associated with distant metastasis or prognosis for survival in tumors. Specifically, the present invention provides a method of determining the risk of distant metastasis or prognosis for survival in a tumor, comprising measuring the expression level of sarcopodin in a tumor tissue. Furthermore, the present invention provides an agent for inhibiting metastasis containing a polynucleotide complementary to an mRNA that encodes sarcopodin or an expression vector capable of expressing the polynucleotide.
    Type: Application
    Filed: May 30, 2008
    Publication date: July 29, 2010
    Applicant: KYOTO UNIVERSITY
    Inventors: Junya Toguchida, Satoshi Nagayama, Moritoshi Furu
  • Publication number: 20070270489
    Abstract: The present invention relates an agent for treating cartilage-related disease comprising as an active ingredient a substance having an EP2 and/or EP3 agonist activity. A substance having an agonist activity to EP2 and/or EP3 has effects of stimulating chondrogenesis, stimulating chondrocyte growth, stimulating chondrocyte differentiation, inhibiting cartilage calcification and inhibiting cartilage degradation, or effects of stimulating integrin mRNA expression, stimulating fibronectin mRNA expression, stimulating D1 mRNA expression and inhibiting osteopontin mRNA expression, and, therefore, is useful as an agent for treating cartilage-related disease.
    Type: Application
    Filed: July 23, 2004
    Publication date: November 22, 2007
    Inventor: Junya Toguchida